Navigation Links
BioMarin to Present at the Credit Suisse Healthcare Conference
Date:11/4/2009

NOVATO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse Healthcare Conference in Phoenix on Wednesday, November 11, 2009 at 12:00 p.m. MST.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of Bi
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...nsure Emergency Deliveries are Transported ,,...eamster members employed by the Philadelphia chapt...ating the public about the unfair labor conditions...delphia,s blood supply at risk. More than 100 emp...terday when their issues were ignored by their emp...
(Date:12/4/2009)..., Ill., Dec. 4 Shared Imaging, LLC...stems and service programs for hospitals and healt...eived The Joint Commission,s Accreditation for Amb...tigious gold seal of approval for quality and safe...s system-wide for its mobile MRI and PET/CT servic...
(Date:12/4/2009)...Md., Dec. 4 PharmAthene,...eloping medical countermeasures against biological...mpany is presenting results of a study demonstrati...ation anthrax model in the New Zealand White (NZW)...ral session at the HHS Public Health Emergency Med...
Breaking Medicine Technology:Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AMDL Diagnostics Inc Enters Into Exclusive Distribution Agreement With Grifols USA LLC to Advance Commercialization of DR 70 Onko Sure 28TM 29 Canc 5327 1AMDL Diagnostics Inc Enters Into Exclusive Distribution Agreement With Grifols USA LLC to Advance Commercialization of DR 70 Onko Sure 28TM 29 Canc 5327 2AMDL Diagnostics Inc Enters Into Exclusive Distribution Agreement With Grifols USA LLC to Advance Commercialization of DR 70 Onko Sure 28TM 29 Canc 5327 3AMDL Diagnostics Inc Enters Into Exclusive Distribution Agreement With Grifols USA LLC to Advance Commercialization of DR 70 Onko Sure 28TM 29 Canc 5327 4Help is Here Express Arrives in Anderson Seneca 5322 1Help is Here Express Arrives in Anderson Seneca 5322 2Elseviers Health Sciences Division and Peking University Medical Press cooperate on book donation 59133 1Elseviers Health Sciences Division and Peking University Medical Press cooperate on book donation 59133 2
(Date:12/4/2009)...han 15 million Americans are recruited annually to...lliance for Human Research Protection (AHRP), and ... , Research institutions view payments to vol... as compensation for potential risks related to pa...inds that volunteers have a very different view of...
(Date:12/4/2009)... exercise, water and fruit consumption leads to s... (HealthDay News) -- Increased exercise, reduced s...st effective weight control strategies for adolesc... 130 adolescents about their weight-control strate... in losing weight and 68 had not. The responses we...
(Date:12/4/2009)...nd surveillance urged for at-risk patient groups ,...me childhood cancers, particularly Ewing sarcomas ...of late recurrence, U.S. researchers have found. ,...ve-year survivors of the most common pediatric can...vivor Study. , The researchers found that the o...
(Date:12/4/2009)... knowledge of risks, many hesitate to take breast .... 4 (HealthDay News) -- Worries about side effects... women at high risk for breast cancer are willing ... a new study finds. , In an effort to inform wo...earchers at the University of Michigan Comprehensi...
(Date:12/4/2009)... , JACKSONVILLE, Fla., Dec. 4 /PRNewswire/ -...d awards for their work in improving the health of...oundation for a Healthy Florida,s 2009 Sapphire Aw...s only statewide award that recognizes and promote...in addressing health disparities within their comm...
Breaking Medicine News(10 mins):Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Top Nonprofits Honored for Improving Health of Floridians 2Health News:Top Nonprofits Honored for Improving Health of Floridians 3
...d over again, it is only tiny gadgets that have ch...orld. Researchers have developed a small device re...lp people with balance // disorder, by giving the ...isorders, a common result of ototoxicity, can affe...
...irus, named human bocavirus, that may be responsib...ildren has been identified by a group of Swedish r...nitiate a systematic // search for all the viruse...ng of viruses to help in speedy diagnosis and appr...
...tive medicine may no longer be truly alternative s... 34,000 readers. The report revealed that Chiropra...ts, including prescription drugs, // by readers wi...pain deemed acupuncture and acupressure less effec...
...hers from Mayo clinic had attributed the rising ra...oing hemodialysis to increased levels of heparin a...e August issue of Mayo Clinic Proceedings // is a ...adverse outcomes also had elevated levels of hepar...
...cessful attempts of scientists to create stem cell...addition to reprogramming to the embryonic state c...on of human embryos for the same. // If futu...technical hurdle, the hybrid cells could theoretic...
...idepressant Seroxat has been linked to increased s...sted that appropriate warning should be given to d...se effect of the drug. // The drug has alread... whom seven attempted to end their life. The resul...
Other Medicine News:
...lexible Impact And Impact2 Pipettors , , Availabl...annel Impact and Impact2 pipettors can effectively...ith the same ergonomic design and superior functio...re equally easy to program for a wide range of liq...
...omic solution and best value in high performance e... and ultra lightweight design reduce hand fatigue ... lever tip ejector , Color coding for easy volum... greater performance use Hamilton AdvanTip Low Ret...
...omic solution and best value in high performance e...n and ultra lightweight design reduce hand fatigue... lever tip ejector, Color coding for easy volume...reater performance use Hamilton AdvanTip Low Reten...
Finnpipette BioControl Single Channel, 200-1000ul
Medicine Products: